<35 | 8 | 10.81% |
35–45 | 26 | 35.13% |
46–55 | 21 | 28.38% |
56–65 | 19 | 25.68% |
Married | 58 | 78.37% |
Single | 5 | 6.77% |
Widow | 11 | 14.86% |
Normal weight | 17 | 22.97% |
Overweight | 26 | 35.17% |
Obese | 31 | 41.89% |
Pre-menopause | 38 | 51.35% |
Post-menopause | 36 | 48.65% |
Yes | 15 | 20.27% |
No | 59 | 79.73% |
Yes | 16 | 21.62% |
No | 58 | 78.38% |
Low level | 47 | 63.51% |
Intermediate level | 18 | 24.32% |
High level | 9 | 12.16% |
0 | 19 | 25.68% |
1 | 47 | 63.51% |
2 | 8 | 10.81% |
3 | 0 | 0.00% |
4 | 0 | 0.00% |
IDC | 67 | 90.54% |
ILC/mixed IDC/ILC | 7 | 9.46% |
IIB | 10 | 13.52% |
IIIA | 31 | 41.89% |
IIIB | 33 | 44.59% |
ER and/or PR positive | 63 | 85.14% |
ER and PR negative | 11 | 14.86% |
Positive | 30 | 40.54% |
Negative | 44 | 59.46% |
Body image | 0.54 |
Sexual functioning | 0.85 |
Breast satisfaction | 0.95 |
Systemic therapy side effects | 0.63 |
Arm symptoms | 0.77 |
Breast symptoms | 0.74 |
Endocrine therapy symptoms | 0.76 |
Skin mucosis symptoms | 0.75 |
Endocrine sexual symptoms | 0.88 |
Future perspective |
Single item |
Functional scales | ||||
Body image | 0.487–0.798 | 0.032–0.638 | 4/4 | |
Sexual functioning | 0.902–0.924 | 0.001–0.027 | 2/2 | |
Breast satisfaction | 0.977–0.978 | −0.041–0.03 | 2/2 | |
Symptoms scales | ||||
Systemic therapy side effects |
0.308–0.743 | 0.002–0.507 | 7/7 | |
Arm symptoms | 0.765–0.872 | 0.022–0.480 | 3/3 | |
Breast symptoms | 0.649–0.827 | 0.016–0.308 | 4/4 | |
Target therapy scales | ||||
Endocrine therapy symptoms |
0.397–0.879 | 0.003–0.773 | 10/10 | |
Skin mucosis symptoms | 0.425–0.796 | 0.055–0.541 | 6/6 | |
Endocrine sexual symptoms | 0.940–0.959 | 0.004–0.635 | 4/4 |